Dosage form of N-acetyl cysteine

Details Dosage form of N-acetyl cysteine Dosage form of N-acetyl cysteine

2001-05-21

2003-09-23

Azpuru, Carlos (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S465000, C424S468000

Reexamination Certificate

active

06623754

ABSTRACT:

BACKGROUND OF INVENTION
Commonly-assigned application Ser. No. 09/329,471, filed Jun. 10, 1999, describes certain rheology modifying polymers derived from acrylic acid, methacrylic acid or analogues which exhibit enhanced controlled release properties when in granulated form. Commonly-assigned application Ser. No. 09/559,687, filed Apr. 27, 2000, teaches that these granulated rheology modifying polymers are particularly well suited for making solid dosage tablets and other articles by direct compression—i.e., by directly compressing a mixture of the tablet ingredients without granulating the mixture first.
SUMMARY OF INVENTION
It has now been found that the above technology is particularly well-suited for making tablets and other solid dosage pharmaceuticals in which N-acetyl cysteine is the active ingredient.
Thus, the present invention provides a directly-compressed, controlled release tablet or other article containing N-acetyl cysteine as the active ingredient. More particularly, the present invention provides a directly-compressed, controlled release tablet or other article containing about 25 to 80 wt. % N-acetyl cysteine, about 5 to 50 wt. % of a granulated, rheology modifying, release-controlling, slightly cross-linked polymer of acrylic acid, methacrylic acid or analogue, and optionally about 0 to 40 wt. % of an additional excipient, which preferably is a directly compressible binder.
In addition the present invention also provides new directly compressible compositions for making such tablets and articles as well as direct compression processes for forming tablets, caplets, and other solid dosage forms known to those skilled in the art.


REFERENCES:
patent: 2798053 (1957-07-01), Brown
patent: 3915921 (1975-10-01), Schlatzer, Jr.
patent: 4267103 (1981-05-01), Cohen
patent: 4968506 (1990-11-01), Appelgren et al.
patent: 4996047 (1991-02-01), Kehelleher et al.
patent: 5145644 (1992-09-01), Park et al.
patent: 5288814 (1994-02-01), Long, II et al.
patent: 5349030 (1994-09-01), Long, II et al.
patent: 5716991 (1998-02-01), Jones
patent: 5753656 (1998-05-01), Sakai et al.
patent: 5766623 (1998-06-01), Ayres et al.
patent: 5852055 (1998-12-01), Jones
patent: 6060486 (2000-05-01), Urashima et al.
patent: WO0006151 (2000-02-01), None
patent: WO0008092 (2000-02-01), None
patent: WO 00/08092 (2000-02-01), None
patent: WO0137808 (2001-05-01), None
patent: WO0182894 (2001-11-01), None
Post Presentation at AAPS, Nov. 1, 2000, W.R. Wilber et al., “Modified-Release Tablets Using Carbomer Resin in Direct Compression”.
BFGoodrich Performance Materials, Carbopol® 71G marketing brochure, Oct. 2000.
H.A. Lieberman et al., editors, “Pharmaceutical Dosage Forms—Tablets”, 1989, pp. 132-137, and 243-245 Marcel Dekker, Inc., New York.

Affiliated with

Also associated with

Rating

Dosage form of N-acetyl cysteine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dosage form of N-acetyl cysteine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosage form of N-acetyl cysteine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3079290